A Multicenter, Randomized, Phase 3 Study Comparing LY3537982 and Pembrolizumab to Placebo and Pembrolizumab as First-Line Treatment in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer with high PD-L1 expression (TPS ≥50%)
Biomarcador: KRASp.G12C
1ª LINHA
Braço A: PDL1 >= 50% (0-LY3537982 + Pembrolizumabe 100 % / Placebo + Pembrolizumabe)
Braço B: PDL1 0-100% (LY3537982 + Pembrolizumabe + Pemetrexede e Platina / Placebo + Pembrolizumabe + Pemetrexede e Platina)
